Literature DB >> 20218877

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

Dimitrios P Kontoyiannis1, Kieren A Marr, Benjamin J Park, Barbara D Alexander, Elias J Anaissie, Thomas J Walsh, James Ito, David R Andes, John W Baddley, Janice M Brown, Lisa M Brumble, Alison G Freifeld, Susan Hadley, Loreen A Herwaldt, Carol A Kauffman, Katherine Knapp, G Marshall Lyon, Vicki A Morrison, Genovefa Papanicolaou, Thomas F Patterson, Trish M Perl, Mindy G Schuster, Randall Walker, Kathleen A Wannemuehler, John R Wingard, Tom M Chiller, Peter G Pappas.   

Abstract

BACKGROUND: The incidence and epidemiology of invasive fungal infections (IFIs), a leading cause of death among hematopoeitic stem cell transplant (HSCT) recipients, are derived mainly from single-institution retrospective studies.
METHODS: The Transplant Associated Infections Surveillance Network, a network of 23 US transplant centers, prospectively enrolled HSCT recipients with proven and probable IFIs occurring between March 2001 and March 2006. We collected denominator data on all HSCTs preformed at each site and clinical, diagnostic, and outcome information for each IFI case. To estimate trends in IFI, we calculated the 12-month cumulative incidence among 9 sequential subcohorts.
RESULTS: We identified 983 IFIs among 875 HSCT recipients. The median age of the patients was 49 years; 60% were male. Invasive aspergillosis (43%), invasive candidiasis (28%), and zygomycosis (8%) were the most common IFIs. Fifty-nine percent and 61% of IFIs were recognized within 60 days of neutropenia and graft-versus-host disease, respectively. Median onset of candidiasis and aspergillosis after HSCT was 61 days and 99 days, respectively. Within a cohort of 16,200 HSCT recipients who received their first transplants between March 2001 and September 2005 and were followed up through March 2006, we identified 718 IFIs in 639 persons. Twelve-month cumulative incidences, based on the first IFI, were 7.7 cases per 100 transplants for matched unrelated allogeneic, 8.1 cases per 100 transplants for mismatched-related allogeneic, 5.8 cases per 100 transplants for matched-related allogeneic, and 1.2 cases per 100 transplants for autologous HSCT.
CONCLUSIONS: In this national prospective surveillance study of IFIs in HSCT recipients, the cumulative incidence was highest for aspergillosis, followed by candidiasis. Understanding the epidemiologic trends and burden of IFIs may lead to improved management strategies and study design.

Entities:  

Mesh:

Year:  2010        PMID: 20218877     DOI: 10.1086/651263

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  395 in total

Review 1.  Sudden death in a patient with bone marrow transplant by a fungus among us.

Authors:  Lemuel Non; Joanna Paula Sta Cruz; Sherilyn Tuazon
Journal:  BMJ Case Rep       Date:  2014-11-12

2.  Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Authors:  Jean El Cheikh
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

3.  Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus.

Authors:  Maged Muhammed; Marta Feldmesser; Lisa F Shubitz; Michail S Lionakis; Anita Sil; Yan Wang; Justin Glavis-Bloom; Russell E Lewis; John N Galgiani; Arturo Casadevall; Dimitrios P Kontoyiannis; Eleftherios Mylonakis
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

4.  Serum (1->3)-β-D-glucan measurement in coccidioidomycosis.

Authors:  George R Thompson; Derek J Bays; Suzanne M Johnson; Stuart H Cohen; Demosthenes Pappagianis; Malcolm A Finkelman
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

5.  Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center (1998-2008): diverse and impactful.

Authors:  G Pongas; G Hamilos; K V Rolston; Dimitrios P Kontoyiannis
Journal:  Support Care Cancer       Date:  2010-12-30       Impact factor: 3.603

Review 6.  Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Authors:  Anna B Halpern; Gary H Lyman; Thomas J Walsh; Dimitrios P Kontoyiannis; Roland B Walter
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

Review 7.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

8.  Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET).

Authors:  C A Kauffman; A G Freifeld; D R Andes; J W Baddley; L Herwaldt; R C Walker; B D Alexander; E J Anaissie; K Benedict; J I Ito; K M Knapp; G M Lyon; K A Marr; V A Morrison; B J Park; T F Patterson; M G Schuster; T M Chiller; P G Pappas
Journal:  Transpl Infect Dis       Date:  2014-03-04       Impact factor: 2.228

9.  Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.

Authors:  Mingjuan Liu; Yan Li; Xiaoli Zhao; Yongqing Zhang; Bing Zhai; Qingyi Zhang; Lijun Wang; Yu Zhao; Honghua Li; Quanshun Wang; Chunji Gao; Wenrong Huang; Li Yu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

10.  Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus.

Authors:  Frédéric Lamoth; Praveen R Juvvadi; Christopher Gehrke; Yohannes G Asfaw; William J Steinbach
Journal:  J Infect Dis       Date:  2013-10-04       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.